Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients

PRECISION BIOSCIENCES INC

2025-Q2 EPS reported -$4.33 revenue$47,000

Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).
Phase 1 ELIMINATE-B trial: PBGENE-HBV showed 47-69% HBsAg reduction in all 3 Cohort 1 patients; one patient had durable ~50% reduction at 7 months.
Cohort 2 safety data showed no Grade>2 AEs; DMC recommended enrolling Cohort 3. Cash runway extended to H2 2027 via operating cost cuts of ~$25M/year.
PBGENE-DMD: FDA granted Rare Pediatric Disease and Orphan Drug designations; IND/CTA filing targeted by end of 2025 with clinical data in 2026.
Total operating expenses fell $3.9M YoY to $21.9M; cash and equivalents $84.8M as of June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.